Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentMORABITO, Fortunato; GENTILE, Massimo; PETRUCCI, Maria Teresa et al.Blood. 2011, Vol 118, Num 22, pp 5759-5766, issn 0006-4971, 8 p.Article

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalPALUMBO, Antonio; BRINGHEN, Sara; GRASSO, Mariella et al.Journal of clinical oncology. 2014, Vol 32, Num 7, pp 634-640, issn 0732-183X, 7 p.Article

Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsBRINGHEN, Sara; LAROCCA, Alessandra; GUGLIELMELLI, Tommasina et al.Blood. 2010, Vol 116, Num 23, pp 4745-4753, issn 0006-4971, 9 p.Article

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma : randomised controlled trial. CommentaryKUMAR, Shaji; PALUMBO, Antonio; GALLI, Monica et al.Lancet (British edition). 2006, Vol 367, Num 9513, issn 0140-6736, 791-792,825-831 [9 p.]Article

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaPALUMBO, Antonio; BERTOLA, Alessandra; MUSTO, Pellegrino et al.Cancer. 2005, Vol 104, Num 7, pp 1428-1433, issn 0008-543X, 6 p.Article

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialPALUMBO, Antonio; BRINGHEN, Sara; CAPALDI, Antonio et al.Blood. 2004, Vol 104, Num 10, pp 3052-3057, issn 0006-4971, 6 p.Article

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaCAVO, Michele; PANTANI, Lucia; NOZZOLI, Chiara et al.Blood. 2012, Vol 120, Num 1, pp 9-19, issn 0006-4971, 11 p.Article

Melphalan 200 mg/m² versus melphalan 100 mg/m² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyPALUMBO, Antonio; BRINGHEN, Sara; LEVI, Anna et al.Blood. 2010, Vol 115, Num 10, pp 1873-1879, issn 0006-4971, 7 p.Article

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled TrialPALUMBO, Antonio; BRINGHEN, Sara; BENEVOLO, Giulia et al.Journal of clinical oncology. 2010, Vol 28, Num 34, pp 5101-5109, issn 0732-183X, 9 p.Article